证券代码：688356 证券简称：键凯科技 公告编号：2023-033 北京键凯科技股份有限公司 第三届董事会第四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 董事会会议召开情况 北京键凯科技股份有限公司（以下简称"公司"）第三届董事会第四次会议通知已于 2023 年 8 月 18 日通过通讯方式送达。会议于 2023 年 8 月 28 日以现场及通讯表决方式 在公司会议室召开。本次会议应出席董事 9 名，实际出席董事 9 名。会议由董事长赵宣 先生主持。本次会议的召开符合《中华人民共和国公司法》等法律、法规、规范性文件 和《公司章程》的有关规定，会议合法、有效。 二、 董事会会议审议情况 本次会议以书面表决方式进行表决。经与会董事认真审议，本次会议审议通过了如 下议案： （一）审议并通过《关于公司 2023 年半年度报告及其摘要的议案》 董事会认真审议了《公司 2023 年半年度报告》及其摘要,认为《公司 2023 年半年度 报告》及其摘要的内容真实、准确、完整地反映了公司 2023 年半年度经营 ...

证券代码：688356 证券简称：键凯科技 公告编号：2023-032 北京键凯科技股份有限公司 关于独立董事连任期满及补选独立董事并 调整董事会专门委员会成员的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、独立董事连任期满 北京键凯科技股份有限公司（以下简称"公司"）董事会近日收到公司独 立董事毕克先生的书面辞职报告。因连任公司独立董事满六年，毕克先生申请辞 去公司独立董事、董事会审计委员会主任委员、薪酬与考核委员会委员的职务。 辞职生效后将不再担任公司任何职务。 毕克先生辞去独立董事职务后，将导致公司独立董事人数未达到董事会总人 数的三分之一，根据《关于在上市公司建立独立董事制度的指导意见》和《公司 章程》的规定，毕克先生辞职将自公司股东大会选举产生新的独立董事后生效。 高巧莉女士尚未参加上海证券交易所科创板独立董事网络课程培训，作为 公司第三届董事会独立董事候选人，高巧莉女士已经承诺参加上交所最近一期独 立董事培训并取得独立董事学习证明，其任职资格和独立性已经上海证券交易所 审核无异议，本议案尚需提交公司股 ...

证券代码：688356 证券简称：键凯科技 公告编号：2023-024 北京键凯科技股份有限公司 关于公司参与设立私募股权专项基金 暨对外投资的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资基金名称：嘉兴仓廪键益创业投资合伙企业（有限合伙）（以下简称"仓 廪键益"或"基金"）。 投资金额、在投资基金中的占比及身份：北京键凯科技股份有限公司（以下 简称"公司"）拟作为有限合伙人以自有资金认缴出资人民币 2,100 万元，出资 比例占基金总认缴出资额的 46.41%。 仓廪键益为专项股权投资基金，该基金将用于认购上海益思妙医疗器械有限 公司股权。 本次投资事项不构成关联交易，也不构成《上市公司重大资产重组管理办法》 规定的重大资产重组。 风险提示： 1、本次公司作为有限合伙人参与投资上述合伙型私募股权专项基金，风险敞口 规模以投资额为限，本次投资无保本及最低收益承诺。 2、基金投资方式主要为股权投资，具有周期较长、流动性较低等特点，公司本 次参与基金的投资回报可能将面临较长的投资回收期。 3、基金所直 ...

证券代码：688356 证券简称：键凯科技 公告编号：2023-023 北京键凯科技股份有限公司 关于首次公开发行部分限售股上市流通的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、本次上市流通的限售股类型 根据中国证券监督管理委员会于 2020 年 7 月 28 日出具的《关于同意北京键 凯科技股份有限公司首次公开发行股票注册的批复》（证监许可[2020]1579 号）， 同意北京键凯科技股份有限公司（以下简称"公司"或"键凯科技"）首次公开 发行股票的注册申请，公司向社会公开发行人民币普通股 15,000,000 股，并于 2020 年 8 月 26 日在上海证券交易所科创板上市交易。首次公开发行股票完成后， 公司总股本为 60,000,000 股，其中有限售条件流通股 46,358,399 股，无限售条 件流通股 13,641,601 股。公司首次公开发行的网下配售的 608,399 股限售股已 于 2021 年 2 月 26 日上市流通。首次公开发行的部分限售股共计 20,987,543 ...

中信证券股份有限公司 关于北京键凯科技股份有限公司 首次公开发行限售股上市流通的核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐机构"）作为北京 键凯科技股份有限公司（以下简称"公司"、"键凯科技"或"发行人"）首次公 开发行股票并在科创板上市的保荐机构。根据《证券发行上市保荐业务管理办法》 《上海证券交易所科创板股票上市规则》以及《科创板上市公司持续监管办法（试 行）》等有关规定，对公司首次公开发行限售股上市流通事项进行了核查，核查 情况如下： 2020 年 7 月 28 日，中国证券监督管理委员会出具《关于同意北京键凯科技 股份有限公司首次公开发行股票注册的批复》（证监许可[2020]1579 号），同意公 司首次向社会公开发行人民币普通股（A 股）1,500 万股（以下简称"首次公开 发行"），并于 2020 年 8 月 26 日在上海证券交易所科创板挂牌上市。公司首次公 开发行后总股本为 60,000,000 股，其中有限售条件流通股 46,358,399 股，无限售 条件流通股 13,641,601 股。公司首次公开发行的网下配售的 608,399 股限售股已 于 2021 年 2 月 ...

Financial Performance - The company reported a revenue of CNY 92,823,711.88 for Q1 2023, representing a year-over-year decrease of 7.95%[5] - Net profit attributable to shareholders was CNY 47,081,919.93, down 10.04% compared to the same period last year[5] - The net profit after deducting non-recurring gains and losses was CNY 43,513,875.16, showing a slight increase of 0.73% year-over-year[5] - Basic earnings per share were CNY 0.78, down 10.34% year-over-year[6] - The net profit for Q1 2023 was CNY 47,081,919.93, down 10.67% from CNY 52,338,062.73 in Q1 2022[18] - The total comprehensive income for Q1 2023 was CNY 46,437,814.52, compared to CNY 51,952,638.01 in Q1 2022[18] Cash Flow - The net cash flow from operating activities was CNY 39,121,377.13, reflecting a decrease of 13.73% compared to the previous year[6] - In Q1 2023, the company's cash inflow from operating activities was CNY 104,689,131.23, an increase of 6.4% compared to CNY 98,319,856.82 in Q1 2022[19] - The net cash flow from operating activities decreased to CNY 39,121,377.13, down 13.5% from CNY 45,349,764.61 in the same period last year[19] - Cash inflow from investment activities was CNY 197,518,140.32, a decrease of 28.6% compared to CNY 276,713,534.05 in Q1 2022[19] - The net cash flow from investment activities was -CNY 140,153,008.76, worsening from -CNY 8,644,110.42 in Q1 2022[19] - The company recorded a net increase in cash and cash equivalents of -CNY 98,645,162.09, compared to a positive increase of CNY 35,182,529.81 in the previous year[19] - The ending balance of cash and cash equivalents was CNY 202,316,882.85, down from CNY 263,039,542.62 at the end of Q1 2022[19] - Total cash outflow from operating activities was CNY 65,567,754.10, an increase of 23.8% from CNY 52,970,092.21 in the same quarter last year[19] - The company obtained CNY 5,000,000.00 in loans during the quarter, with a net cash flow from financing activities of CNY 3,733,121.08[19] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,338,167,702.38, an increase of 2.73% from the end of the previous year[6] - The company's cash and cash equivalents decreased to CNY 209,460,204.13 from CNY 309,629,593.24 at the end of 2022[15] - Total assets increased to CNY 1,338,167,702.38 as of March 31, 2023, compared to CNY 1,302,559,885.18 at the end of 2022[16] - The total liabilities decreased to CNY 61,465,026.38 from CNY 77,801,659.23 at the end of 2022[16] Research and Development - R&D expenses totaled CNY 13,302,499.84, a decrease of 30.47% compared to the same period last year[6] - R&D expenses accounted for 14.33% of revenue, down 4.64 percentage points year-over-year[6] - R&D expenses for the quarter amounted to CNY 13,302.50 million, a decrease of 30.47% compared to CNY 19,130.96 million in the same period last year[18] Shareholder Information - The company had a total of 5,472 common shareholders at the end of the reporting period[10] Sales Performance - Product sales revenue was CNY 7,653.43 million, down 15.09% year-over-year, while technical service revenue increased by 51.99% to CNY 1,612.06 million[13] - The company reported a decrease in foreign sales revenue by 22.67% to CNY 4,761.26 million, attributed to logistics delays and a significant drop in LNP product orders[13] Other Financial Metrics - The weighted average return on equity was 3.76%, a decrease of 1.09 percentage points compared to the previous year[6] - The company confirmed share-based payment expenses of CNY 627.47 million, down from CNY 893.19 million in the previous year[13] - The company received CNY 11,073,557.52 in tax refunds, significantly higher than CNY 4,822,238.45 in Q1 2022, marking an increase of 129.8%[19] - The company did not report any net profit from the merged entity prior to the merger, consistent with the previous period[19]

重要内容提示： 投资者可于 2023 年 04 月 18 日(星期二)至 04 月 24 日(星期一)16:00 前登录 上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@jenkem.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 北京键凯科技股份有限公司（以下简称"公司"）已于 2023 年 3 月 31 日发 布公司 2022 年年度报告，为便于广大投资者更全面深入地了解公司 2022 年度经 营成果、财务状况，公司计划于 2023 年 04 月 25 日下午 14:00-15:00 举行 2022 年度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2022 年度的经营成果 及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范围内 就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 证券代码：688356 证券简称：键凯科技 公告编号：2023-017 北京键凯科技股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 ...

北京键凯科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |-------------------------|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：688356 证券简称：键凯科技 单位：元 币种：人民币 2022 年第三季度报告 北京键凯科技股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 本报告期 年初至报告期 | --- | --- | --- | --- | --- | |------------------------------------------------|----------------|------------------------------|----------------|------------------------------ ...

Financial Performance - The company reported a revenue of RMB 500 million for the first half of 2022, representing a year-on-year increase of 20%[2]. - The company's operating revenue for the first half of 2022 was approximately ¥214.77 million, representing a year-on-year increase of 37.91% compared to ¥155.74 million in the same period last year[26]. - The net profit attributable to shareholders for the same period was approximately ¥111.40 million, reflecting a growth of 38.15% from ¥80.64 million year-on-year[26]. - The gross margin for the first half of 2022 was reported at 45%, a slight increase from 42% in the same period last year[2]. - The comprehensive gross margin for the first half of 2022 was 85.20%, an increase of 0.51 percentage points from the same period in 2021[62]. - The net cash flow from operating activities surged by 173.07%, reaching approximately ¥151.14 million, compared to ¥55.35 million in the previous year[26]. - Total assets increased by 8.11% to approximately ¥1.19 billion, while net assets attributable to shareholders grew by 7.41% to approximately ¥1.13 billion[26]. - Basic earnings per share rose by 38.81% to ¥1.86, while diluted earnings per share increased by 37.31% to ¥1.84[26]. Research and Development - Research and development efforts focused on new technologies, with an investment of RMB 50 million in the development of lipid nanoparticles (LNPs) for drug delivery systems[2]. - Research and development expenses accounted for 19.99% of operating revenue, up from 11.64% in the previous year, indicating a significant increase of 8.35 percentage points[26]. - The total R&D investment increased by 136.82% year-on-year, amounting to ¥42,936,514.43, with R&D expenses accounting for 19.99% of operating revenue, up from 11.64%[49][50]. - The number of R&D personnel increased from 35 to 61, representing 26.18% of the total workforce, with an average salary of ¥12.33[57]. - The company completed the development of 61 new structural derivatives and 60 analytical methods during the reporting period, enhancing its technological capabilities[58]. - The company has applied for 16 new invention patents during the reporting period, with a total of 61 applications and 96 patents granted[48]. - The company aims to complete clinical trials for JK-2122H and continue clinical research for JK-1119I, which has received ¥11,853,508.40 in current period investment[54]. Market Expansion and Product Development - The company provided a future outlook, projecting a revenue growth of 25% for the second half of 2022, driven by new product launches and market expansion[2]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2023[2]. - A strategic acquisition of a local biotech firm is expected to enhance the company's product portfolio and increase market competitiveness[2]. - The company aims to launch three new products in the next quarter, which are anticipated to contribute an additional RMB 100 million in revenue[2]. - The company has developed innovative PEG-modified drugs and medical devices, which are currently in preclinical or Phase II clinical research stages[31]. - The company has developed several PEG-modified drugs and Class III medical devices, including PEG-irinotecan, which has entered Phase II clinical trials, and the medical device project JK-2122H, which is currently in clinical stages[34]. Environmental Commitment - The company emphasizes its commitment to environmental protection, adhering to national and local regulations during production[98]. - Key pollutants generated during production include wastewater, waste gas, and noise, with effective treatment measures implemented[98]. - The company operates five high exhaust stacks for waste gas, ensuring emissions meet regulatory standards[98]. - The company’s wastewater treatment system effectively handles production wastewater and domestic sewage, ensuring compliance with environmental regulations[104]. - The company has a comprehensive environmental management system in place, including protocols for hazardous waste disposal and environmental risk assessments[110]. Shareholder and Governance Policies - The company reported a commitment to not transfer or manage shares for 36 months post-IPO, with an automatic extension of 6 months if stock prices fall below the IPO price for 20 consecutive trading days within the first 6 months[121]. - Shareholders are restricted from transferring shares for 12 months post-IPO, ensuring stability during the initial trading period[123]. - The company will comply with regulations regarding share transfers and will publicly apologize if commitments are not fulfilled, with potential compensation for losses incurred by investors[125]. - The company has committed to a profit distribution policy that emphasizes reasonable returns to investors, ensuring that cash dividends will account for at least 80% of profits during mature stages without significant capital expenditures[156]. - The company will prioritize cash dividends when conditions allow, with stock dividends being considered only when the stock price is deemed misaligned with the company's capital structure[159]. - The company will maintain a continuous and stable profit distribution policy, taking into account the opinions of independent directors and public investors[156]. Financial Management and Investments - The company has utilized a total of RMB 154,649,800 in cash management from raised funds, with an expected annualized return rate ranging from 1.78% to 3.29% across various investment products[180][182][183]. - The company has invested in various financial products, including structured deposits and wealth management products, with a focus on capital preservation and liquidity[180][182]. - The company’s cash management strategy includes investments in safe and liquid products, ensuring the security of raised funds[180]. - The total amount used for share buybacks in a single fiscal year cannot exceed 50% of the net profit attributable to the parent company from the previous year[141].